Lung Cancer
Conditions
Interventions
Experimental group (Surgery after neoadjuvant immunotherapy):None
Control group (Direct Surgery):None
Observation group (Neoadjuvant immunotherapy):None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Voluntary consent and signing of the informed consent form; 2.Age between 18 and 80 years old (inclusive); 3.Complete information on tumor location, pathological type, etc. of the patient; 4.Availability of tissue samples or peripheral blood samples; 5.Patient's agreement to be enrolled and provision of postoperative follow-up information; 6.No EGFR or ALK driver mutations.
Exclusion criteria
Exclusion criteria: 1.Concurrent with other malignant tumors; 2.Pregnant women or lactating women, or other patients not suitable for participation in the study; 3.Patients who have previously received chemotherapy, targeted therapy or lung surgery for lung cancer; 4.Those who have undergone organ transplantation, hematopoietic stem cell transplantation, or received blood transfusion within three months; 5.Unable to obtain tissue and cell pathological diagnosis results; 6.Other reasons deemed unsuitable for clinical trials by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CTC;Gene expression; | — |
Secondary
| Measure | Time frame |
|---|---|
| PD-L1 staining;Gene mutation;TCR; | — |
Countries
China
Contacts
Public ContactChao Chen
Peking University Shenzhen Hospital
Outcome results
None listed